cjc 1295 ipamorelin gh igf 1 increase studies CJC-1295 DAC - Huma Peptide
Description
(Endocrine Reviews, 1991) documented that combined GHRH + GHS-R agonist administration produces GH release 2-5 fold greater than either compound alone, providing the scientific rationale for the CJC-1295 ipamorelin blend approach
Remember for research purposes only, not for human consumption, and document chain of custody throughout your protocol
Relative contraindications (metformin use, PPIs, H2-blockers) warrant monitoring but do not always prevent treatment
Garbincius and Elrod, 2022)
